This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mikulec, K. H. Articles by Carmelli, D. Search for Related Content PubMed PubMed Citation Articles by Mikulec, K. H. Articles by Carmelli, D.

Relationship of Endogenous Sex Hormones to Coronary Heart Disease: A Twin Study

Department of Medicine (K.H.M., R.M.), Stanford University School of Medicine, Stanford, California 94305; The Geriatrics Research, Education & Clinical Center (L.H., R.M.), Palo Alto Veterans Affairs Medical Center, Palo Alto, California 94304; Center for Health Sciences (R.E.K., H.J., G.E.S., D.C.), SRI International, Menlo Park, California 94025; and Department of Medical and Molecular Genetics (T.R.), Indiana University School of Medicine, Indianapolis, Indiana 46202

Address all correspondence and requests for reprints to: Katharine H. Mikulec, M.D., Brigham and Women’s Hospital, Division of Endocrinology, Diabetes, and Hypertension, 221 Longwood Avenue, Boston, Massachusetts 02115. E-mail: kmikulec{at}partners.org.

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
We examined the association between endogenous sex hormones (estradiol, estrone, testosterone, and SHBG) and coronary heart disease (CHD) in white male twins. Stored plasma samples were available for 566 participants of the National Heart, Lung, and Blood Institute Twin Study, a longitudinal study of cardiovascular disease in male twins. Twenty-eight of these individuals were lost to follow-up, and outcome data were missing. Of the remaining 538 participants, 78 had CHD at baseline, and 154 subsequently developed CHD over 20 yr of follow-up. We observed no differences in mean unadjusted or age- and body mass index-adjusted log-transformed sex hormone concentrations for participants with and without CHD (all P > 0.08). Quartile and median split analyses revealed no significant association between any of the sex hormones and either prevalent or incident CHD. The discordant monozygotic twins showed no significant case-control group difference in estradiol, estrone, testosterone, and SHBG (all P > 0.3). The positive and negative concordant twin pairs had similar values for each of the sex hormones (all P > 0.3). We observed no relationship between endogenous sex hormone concentrations and prevalent or incident CHD in this sample of male twins.

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
IT HAS BEEN recognized for many years that men are at higher risk for developing coronary heart disease (CHD) than women. The male-to-female ratio for fatal CHD is consistently around 2:1 in various countries with different lifestyles and rates of heart disease (1). The sex difference in CHD incidence persists after taking into account common CHD risk factors (2, 3, 4). CHD is rare among premenopausal women, and the Framingham Study revealed that the incidence rate of CHD in postmenopausal women is more than double that in premenopausal women of the same age (5, 6). These findings have led to the hypothesis that endogenous sex hormones may play a role in CHD in men and women. In particular, it has been postulated that estrogens provide protection against CHD; however, this remains to be proven and continues to be an area of controversy.

The Coronary Drug Project, a large multi-center trial initiated in 1965, examined whether exogenous estrogen prevented recurrent myocardial infarction (MI) in men who had already experienced one or more MIs. A 5.0-mg/d estrogen group was discontinued after an average of 18 months of treatment because of a higher incidence of MI. A 2.5-mg/d estrogen group was discontinued after 56 months because there was no change in incidence of MI, and there were trends toward an increased incidence of pulmonary embolism and thromboembolism (7, 8).

In addition, Phillips (9) observed signs of feminization and high endogenous estrogen concentrations among young men who had survived an MI. This finding prompted a number of investigators to study the association of endogenous sex hormone concentrations and CHD in men. In several case-control studies, cases with a prior history of MI were found to have elevated circulating concentrations of total estradiol and/or estrone (9, 10, 11, 12, 13, 14, 15, 16, 17). These findings led to the hypothesis that high estrogen exposure may actually increase the risk of CHD. However, these were hospital-based case-control studies, so causality could not be inferred. Two population-based case-control studies showed conflicting results with regard to estradiol and CHD in men; one showed increased concentrations among cases, and one showed no difference (18, 19). Neither study showed an association between testosterone and CHD.

No consistent association has been found between endogenous sex hormones and CHD in men diagnosed by angiography. Of six case-control studies that measured estradiol and/or testosterone, one observed high estradiol values and normal testosterone values in cases, two reported that cases had normal estradiol values and low testosterone values, and three found no significant between-group difference in either estradiol or testosterone (11, 12, 20, 21, 22, 23).

Of eight prospective studies (seven in men and one in men and women) in which baseline concentrations of one or more sex hormones and/or SHBG were examined in relation to the subsequent development of CHD, none showed a significant association (24, 25, 26, 27, 28, 29, 30, 31).

We had the opportunity to apply a unique analytic tool to this question using a large cohort of well-characterized male twins for whom stored plasma samples were available and the occurrence of CHD events was known. Studies of monozygotic (MZ) twin pairs are powerful because they eliminate many sources of variation (e.g. differences in genetic factors and in intrauterine and early environment influences) that are inherent in ordinary matched case-control studies of unrelated individuals. The results of this analysis are reported here.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Study population

The National Heart, Lung, and Blood Institute Twin Study is a longitudinal study of cardiovascular disease in 514 pairs of male twins. The sample was drawn from a population-based registry of almost 16,000 pairs of white, male, Veteran twin pairs created and maintained by the Medical Follow-Up Agency of the National Academy of Sciences-National Research Council. The twins were born between 1917 and 1927 and were 43–56 yr of age when first examined between 1969 and 1973 at five research centers in the United States. Details of the study’s design and methods have been published elsewhere (32, 33). The protocol was approved by the Institutional Review Board, and all participants gave written informed consent. Four follow-up examinations have been completed (exam 2, 1981–1982; exam 3, 1986–1987; exam 4, 1995–1997; and exam 5, 1999–2000).

Data collection

Study protocol at each of the five examinations was similar. Attempts were made to see both members of each twin pair on the same day. A structured questionnaire was administered to determine health history and relevant lifestyle behaviors; height, weight, and systolic (SBP) and diastolic blood pressure were measured; and a 12-lead electrocardiogram was recorded. Blood samples were collected at the first three examinations after an overnight fast. Total, high-density lipoprotein (HDL) and low-density lipoprotein cholesterol and triglyceride concentrations were measured using the North American Lipid Research Clinics methodology. EDTA plasma was frozen at -70 C.

At each examination, subjects were interviewed by a physician who completed a medical history questionnaire that included questions about cardiovascular events and procedures. Medical records were obtained if subjects reported cardiovascular or cerebrovascular disease or if subjects reported hospitalizations or procedures relating to possible cardiovascular or cerebrovascular disease. At examinations 1, 2, and 3, two independent physicians reviewed the questionnaires and medical records. At examinations 4 and 5, one physician reviewed the questionnaires and medical records. Based on subject responses and review of medical records, physicians assigned corresponding International Classification of Diseases, Ninth Revision (ICD-9) codes. Death certificates or ICD-9 coding by the National Death Index were obtained for nearly all decedents. Death certificates were coded for underlying cause of death using ICD-9. In the present analysis, CHD is defined as ICD-9 codes 410–414. Subjects were considered lost to follow-up if they did not attend a subsequent examination and a death certificate or coding from the National Death Index was not available.

Between 2001 and 2002, estradiol, estrone, testosterone, and SHBG concentrations were measured in stored plasma samples from examinations 2 (1981–1982) or 3 (1986–1987). Specimens were from the same examination for both members of each twin pair. Variation in the amount of stored plasma available for hormone analysis accounted for missing data on a small number of participants, as shown in Table 1.

Hormone assays were carried out in the laboratory of one of the authors (R.M.) at the Palo Alto Veterans Affairs Heath Care System, as previously reported (34). Reagent kits were generously provided by Diagnostics Systems Laboratories, Inc. (Webster, TX). Attempts were made to run samples from both members of each twin pair in the same assay batch. Laboratory personnel were blinded to disease status and zygosity. Estradiol was measured by third-generation RIA, and the sensitivity and the intra- and interassay coefficients of variation were 0.6 pg/ml, 11.1%, and 14.1%, respectively. Estrone was measured by RIA, and the sensitivity and the intra- and interassay coefficients of variation were 1.2 pg/ml, 12.8%, and 11.3%, respectively. Total testosterone was measured by RIA, and the sensitivity and the intra- and interassay coefficients of variation were 0.08 ng/ml, 6.9%, and 10.8%, respectively. SHBG was measured by immunoradiometric assay, and the sensitivity and the intra- and interassay variation were 3 nmol/liter, 6.9%, and 7.0%, respectively.

Statistical analysis

The present analysis explores the association between sex hormone concentrations and CHD (ICD-9 codes 410–414) among subjects with follow-up, regardless of their CHD status at baseline. The SAS statistical package (SAS Institute, Cary, NC) was used for data analysis. Because of deviations from normality, logarithmic transformations of raw hormone concentration values were conducted. Hormone values greater than 3 SD from the logged mean were considered to be outliers and were not included in the present analysis.

We examined the relationship between hormone values and potential confounders using Pearson correlation analysis. A t test statistic was used to compare mean levels of established CHD risk factors between the CHD and non-CHD groups. The Mantel-Haenszel ² statistic was used to test for the association between treatment of hypertension and CHD status. An F test adjusted for the relationship of correlated observations was used to compare crude hormone mean levels between the CHD and non-CHD groups. A similar test was used to compare means adjusted for age and body mass index (BMI) between the CHD and non-CHD groups. We repeated these comparisons using PROC MIXED to account for the dependence among twins within pairs. The PROC RANK was used to identify quartile and median split membership. The association between quartile rank and CHD was examined for trend using the Mantel-Haenszel ² statistic. The relationship between median split and CHD was examined using a ² test. Multiple logistic regression analysis was performed for each sex hormone with the sex hormone as the independent variable, age and BMI as covariates, and CHD as the outcome variable. Baseline prevalence and incident CHD were first analyzed together and then analyzed separately. To estimate the concentrations of bioavailable estradiol and bioavailable testosterone, the ratio of total hormone to SHBG was calculated.

The analysis involving the MZ twins discordant for CHD (i.e. pairs in which one has CHD and the other sibling does not have CHD) and concordant for CHD (i.e. pairs in which both have CHD or both do not have CHD) was done in two steps. First, an F test that adjusted for the relationship of correlated observations was used to compare the means between the CHD and non-CHD members of the discordant twin pairs. This was followed by a comparison of the positive-concordant and negative-concordant twin pairs’ means via a similar F-test procedure. We repeated these comparisons using PROC MIXED with pair number being the group effect and individual twins within a pair representing repeated observations.

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Twin subjects analyzed as individuals

Hormone data were available for 566 subjects. Twenty-eight of these individuals were lost to follow-up, and outcome data were missing. Of the remaining 538 subjects, 250 came from 125 MZ twin pairs, 270 came from 135 dizygotic (DZ) twin pairs, and 18 were individuals for whom hormone data were not available for their twin brother. Baseline characteristics and mean hormone concentrations are shown in Table 1. The sex hormones were significantly associated with a group of established CHD risk factors (Table 2).

Table 3 shows mean unadjusted and age-BMI-adjusted log-transformed hormone concentrations for subjects with and without CHD. We observed no between-group differences in sex hormone values in the present sample (all P > 0.08). These results were confirmed after taking into account the dependence within twin pairs.

View larger version (44K): [in this window] [in a new window]   FIG. 1. Prevalence of CHD by quartiles of estradiol, estrone, testosterone, and SHBG (all P > 0.1).

Baseline prevalence and incident CHD events were analyzed separately. Quartile and median split analyses revealed no significant association between any of the sex hormones and either of the CHD outcomes.

Twin pair analyses

Table 4 shows the mean hormone concentrations for MZ twins who were discordant and concordant for CHD. The discordant MZ twins, representing genetically matched cases and controls, showed no significant case-control group difference in estradiol, estrone, testosterone, or SHBG (all P > 0.3). The positive and negative concordant twin pairs had similar values for estradiol, estrone, testosterone, and SHBG (all P > 0.3). We repeated the comparison of discordant pairs using PROC MIXED for MZ pairs and then again for MZ and DZ pairs combined. As expected, all P values were nonsignificant. We also repeated the comparison of positive and negative concordant twin pairs using PROC MIXED for MZ pairs and then again for MZ and DZ pairs combined. As expected, all P values were nonsignificant.

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

First, MZ twins discordant for CHD represent cases and controls matched for genetics, intrauterine environment, and early environment. This model eliminates many sources of variation that are inherent in ordinary case-control studies, most notably genetic make-up.

Second, most of the previously published case-control studies in men were hospital-based, and in several of these studies, blood samples were drawn within days of acute MI (11, 13, 14, 15, 16). By contrast, the subjects in our study were ambulatory without evidence of acute illness at the time of phlebotomy. Elevated estrogen concentrations in the setting of acute MI may be related to general stress rather than to CHD. In men, 95% of daily estrone production is derived from aromatization of the adrenal androgen, androstenedione, and as such, it is highly responsive to adrenal stimulation by ACTH (35, 36). Estrone production is increased in intensive care unit patients who do not have apparent CHD (13), and estrone and urinary catecholamines are significantly correlated in acutely ill subjects (16). Estradiol, by contrast, does not appear to be under the direct control of ACTH (35, 36, 37), although some estradiol is produced from circulating estrone (38). It is also likely that medications administered during hospitalization for acute MI may influence estradiol measurements. Thus, general stress and medications may have confounded the sex hormone measurements of hospital-based case-control studies.

There are several important limitations of the current twin study. For each subject, hormone measurements were made on a single plasma sample. Because steroid hormone concentrations undergo substantial daily fluctuation, a single hormone measurement may not suffice to accurately describe an individual’s overall hormone status. Thus, multiple specimens may be needed to assess the overall hormone status of an individual (2, 24). However, the impact of such fluctuation is minimized in this study by the large number of subjects.

A second methodological issue in our study is sample deterioration resulting from the storage of plasma samples for 15–22 yr before hormone measurement. It has been suggested that estradiol and estrone values decrease with time in storage, even at -70 C (24, 26, 39). We note, however, that the values we report for estradiol, testosterone, and SHBG fall within expected ranges for normal men, although for estrone, the values are slightly low.

Total estradiol and total testosterone were determined, but total measurements may not estimate hormone exposure as well as measurements of bioavailable or free hormone. Attempts were made to approximate bioavailable estradiol and testosterone by calculating the ratios between the total hormones and SHBG. Such analyses also revealed no significant associations with CHD, but we cannot exclude the possibility that such relationships would have emerged if we had directly assessed bioavailable or free hormone concentrations.

Many of the prior studies investigating sex hormones and CHD share these same potential shortcomings. There is no reason to believe, however, that male individuals with or without CHD would be preferentially vulnerable to any of these potential confounders. It is most likely that all subjects would be similarly affected and that valid relationships could still emerge despite these issues.

Although the results of this study do not confirm a relationship between sex hormone status and CHD, multiple lines of evidence support the hypothesis that there should be an association. High-affinity estradiol receptors are present in both vascular smooth muscle and endothelium (40, 41). We know that estrogens inhibit smooth muscle proliferation (42) and decrease smooth muscle tone (43). Estrogens enhance the release of nitric oxide and prostacyclin from endothelial cells, thus inducing vasodilation (44, 45, 46). Furthermore, estrogens exert indirect effects on the cardiovascular system through their influence on lipoprotein metabolism and the coagulation, fibrinolytic, and antioxidant systems (47). Thus, plausible mechanisms exist for an estrogen effect on CHD. In addition, a 31-yr-old man with estrogen unresponsiveness due to a mutation in the estrogen receptor- was reported to have early coronary calcifications (48) and peripheral endothelial dysfunction as shown by absence of flow-mediated vasodilation in the brachial artery (49), thus providing additional evidence for a role of estrogen in cardiovascular health in men.

It may be that hormone concentrations per se do not portray an integrated view of hormone action. Other variables, such as coactivators, corepressors, hormone metabolism, receptor polymorphism, and receptor number make important contributions to hormonal status (44, 47). In addition, the pattern of hormone exposure may also be important. In premenopausal women, estradiol concentrations range from 40–200 pg/ml in the follicular phase and from 250–500 pg/ml at the time of ovulation (44). Several hormones, such as gonadotropin-releasing hormone (50) and PTH (51, 52), are known to exert dramatically different influences when presented to their target tissues in an intermittent or continuous fashion. Perhaps a similar phenomenon occurs with sex hormones, and this may be a fruitful area for additional research.

	Footnotes

 
Supported in part by the National Heart, Lung, and Blood Institute Grant R01-HL51429 and by the Department of Veteran Affairs.

Current address for K.H.M.: Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts 02115.

Current address for R.M.: Eli Lilly & Company, Indianapolis, Indiana 46285.

Abbreviations: BMI, Body mass index; CHD, coronary heart disease; DZ, dizygotic; HDL, high-density lipoprotein; ICD-9, International Classification of Diseases, Ninth Revision; MI, myocardial infarction; MZ, monozygotic; SBP, systolic blood pressure.

Received July 31, 2003.

Accepted November 24, 2003.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 

1. Kalin MF, Zumoff B 1990 Sex hormones and coronary disease: a review of the clinical studies. Steroids 55:330–352[CrossRef][Medline]
2. Barrett-Connor E 1997 Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95:252–264[Free Full Text]
3. Isles CG, Hole DJ, Hawthorne VM, Lever AF 1992 Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 339:702–706[CrossRef][Medline]
4. Wingard DL, Suarez L, Barrett-Connor E 1983 The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol 117:165–172[Abstract/Free Full Text]
5. Kannel WB, Hjortland MC, McNamara PM, Gordon T 1976 Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85:447–452[Medline]
6. Gordon T, Kannel WB, Hjortland MC, McNamara PM 1978 Menopause and coronary heart disease: the Framingham Study. Ann Intern Med 89:157–161[Medline]
7. The Coronary Drug Project 1970 Initial findings leading to modifications of its research protocol. JAMA 214:1303–1313[CrossRef][Medline]
8. The Coronary Drug Project 1973 Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA 226:652–657[CrossRef][Medline]
9. Phillips GB 1976 Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men. Lancet 2:14–18[Medline]
10. Entrican JH, Beach C, Carroll D, Klopper A, Mackie M, Douglas AS 1978 Raised plasma oestradiol and oestrone levels in young survivors of myocardial infarction. Lancet 2:487–490[CrossRef][Medline]
11. Luria MH, Johnson MW, Pego R, Seuc CA, Manubens SJ, Wieland MR, Wieland RG 1982 Relationship between sex hormones, myocardial infarction, and occlusive coronary disease. Arch Intern Med 142:42–44[Abstract]
12. Zumoff B, Troxler RG, O’Connor J, Rosenfeld RS, Kream J, Levin J, Hickman JR, Sloan AM, Walker W, Cook RL, Fukushima DK 1982 Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis 2:58–67[Abstract/Free Full Text]
13. Klaiber EL, Broverman DM, Haffajee CI, Hochman JS, Sacks GM, Dalen JE 1982 Serum estrogen levels in men with acute myocardial infarction. Am J Med 73:872–881[CrossRef][Medline]
14. Labropoulos B, Velonakis E, Oekonomakos P, Laskaris J, Katsimades D 1982 Serum sex hormones in patients with coronary disease and their relationship to known factors causing atherosclerosis. Cardiology 69:98–103[Medline]
15. Aksut SV, Aksut G, Karamehmetoglu A, Oram E 1986 The determination of serum estradiol, testosterone and progesterone in acute myocardial infarction. Jpn Heart J 27:825–837[Medline]
16. Lindholm J, Eldrup E, Winkel P 1990 Variability in plasma oestrogen concentrations in men with a myocardial infarction. Dan Med Bull 37:552–556[Medline]
17. Phillips GB, Pinkernell BH, Jing TY 1996 The association of hyperestrogenemia with coronary thrombosis in men. Arterioscler Thromb Vasc Biol 16:1383–1387[Abstract/Free Full Text]
18. Phillips GB, Castelli WP, Abbott RD, McNamara PM 1983 Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med 74:863–869[CrossRef][Medline]
19. Heller RF, Jacobs HS, Vermeulen A, Deslypere JP 1981 Androgens, oestrogens, and coronary heart disease. Br Med J (Clin Res Ed) 282:438–439[Medline]
20. Chute CG, Baron JA, Plymate SR, Kiel DP, Pavia AT, Lozner EC, O’Keefe T, MacDonald GJ 1987 Sex hormones and coronary artery disease. Am J Med 83:853–859[CrossRef][Medline]
21. Phillips GB, Pinkernell BH, Jing TY 1994 The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 14:701–706[Abstract/Free Full Text]
22. Goldberg RJ, Gore JM, Zive M, Brady P, Klaiber E, Broverman D, Ockene IS, Dalen JE 1987 Serum estradiol and coronary artery disease. Am J Med 82:1–4
23. Kabakci G, Yildirir A, Can I, Unsal I, Erbas B 1999 Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology 92:221–225[CrossRef][Medline]
24. Cauley JA, Gutai JP, Kuller LH, Dai WS 1987 Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 60:771–777[CrossRef][Medline]
25. Barrett-Connor E, Khaw KT 1988 Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539–545[Abstract/Free Full Text]
26. Phillips GB, Yano K, Stemmermann GN 1988 Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol 41:1151–1156[CrossRef][Medline]
27. Eldrup E, Winkel P, Lindholm J, Bentzon MW, Jensen G, Schnohr P 1989 Coronary risk factors, development of myocardial infarction, and plasma oestrogens: a prospective case-control study in men. J Intern Med 225:367–372[Medline]
28. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM 1990 Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 11:460–470[Abstract/Free Full Text]
29. Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D 1993 Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb 13:517–520[Abstract/Free Full Text]
30. Hautanen A, Manttari M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H 1994 Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 105:191–200[CrossRef][Medline]
31. Goodman-Gruen D, Barrett-Connor E 1996 A prospective study of sex hormone-binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women. J Clin Endocrinol Metab 81:2999–3003[Abstract]
32. Jablon S, Neel JV, Gershowitz H, Atkinson GF 1967 The NAS-NRC twin panel: methods of construction of the panel, zygosity diagnosis, and proposed use. Am J Hum Genet 19:133–161[Medline]
33. Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, Kannel WB, Rosenman R, Schwartz JT, Wagner JO 1977 The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol 106:284–285[Abstract/Free Full Text]
34. Cooper CS, Taaffe DR, Guido D, Packer E, Holloway L, Marcus R 1998 Relationship of chronic endurance exercise to the somatotropic and sex hormone status of older men. Eur J Endocrinol 138:517–523[Abstract]
35. Saez JM, Morera AM, Dazord A, Bertrand J 1972 Adrenal and testicular contribution to plasma oestrogens. J Endocrinol 55:41–49[Medline]
36. Baird DT, Uno A, Melby JC 1969 Adrenal secretion of androgens and oestrogens. J Endocrinol 45:135–136[Medline]
37. Pratt JH, Longcope C 1978 Effect of adrenocorticotropin on production rates and metabolic clearance rates of testosterone and estradiol. J Clin Endocrinol Metab 47:307–313[Medline]
38. Marcus R, Korenman SG 1976 Estrogens and the human male. Annu Rev Med 27:357–370[CrossRef][Medline]
39. Phillips GB, Yano K, Stemmermann GN 1984 Decrease in serum estradiol values with storage. N Engl J Med 311:1635[Medline]
40. Karas RH, Patterson BL, Mendelsohn ME 1994 Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89:1943–1950[Abstract/Free Full Text]
41. Venkov CD, Rankin AB, Vaughan DE 1996 Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 94:727–733[Abstract/Free Full Text]
42. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV 1997 Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 272:H1996–H2003
43. White RE, Darkow DJ, Lang JL 1995 Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 77:936–942[Abstract/Free Full Text]
44. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC 2002 Production and actions of estrogens. N Engl J Med 346:340–352[Free Full Text]
45. Moncada S, Higgs A 1993 The L-arginine-nitric oxide pathway. N Engl J Med 329:2002–2012[Free Full Text]
46. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I 1999 Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor localized in caveolae. Biochem Biophys Res Commun 263:257–262[CrossRef][Medline]
47. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801–1811[Free Full Text]
48. Sudhir K, Chou TM, Chatterjee K, Smith EP, Williams TC, Kane JP, Malloy MJ, Korach KS, Rubanyi GM 1997 Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96:3774–3777[Abstract/Free Full Text]
49. Sudhir K, Chou TM, Messina LM, Hutchison SJ, Korach KS, Chatterjee K, Rubanyi GM 1997 Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349:1146–1147[CrossRef][Medline]
50. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E 1978 Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 202:631–633[Abstract/Free Full Text]
51. Tam CS, Heersche JN, Murray TM, Parsons JA 1982 Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506–512[Abstract]
52. Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J, Stevenson RW, Zanelli JM 1983 Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112:1000–1006[Abstract]

This article has been cited by other articles:

				K.-T. Khaw, M. Dowsett, E. Folkerd, S. Bingham, N. Wareham, R. Luben, A. Welch, and N. Day Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study Circulation, December 4, 2007; 116(23): 2694 - 2701. [Abstract] [Full Text] [PDF]

				R. D. Abbott, L. J. Launer, B. L. Rodriguez, G. W. Ross, P.W.F. Wilson, K. H. Masaki, D. Strozyk, J. D. Curb, K. Yano, J. S. Popper, et al. Serum estradiol and risk of stroke in elderly men Neurology, February 20, 2007; 68(8): 563 - 568. [Abstract] [Full Text] [PDF]

				C. N. Lessov-Schlaggar, T. Reed, G. E. Swan, R. E. Krasnow, C. DeCarli, R. Marcus, L. Holloway, P. A. Wolf, and D. Carmelli Association of sex steroid hormones with brain morphology and cognition in healthy elderly men Neurology, November 22, 2005; 65(10): 1591 - 1596. [Abstract] [Full Text] [PDF]

				B. Galobardes, G. D. Smith, M. Jeffreys, S. Kinra, and P. McCarron Acne in Adolescence and Cause-specific Mortality: Lower Coronary Heart Disease but Higher Prostate Cancer Mortality: The Glasgow Alumni Cohort Study Am. J. Epidemiol., June 15, 2005; 161(12): 1094 - 1101. [Abstract] [Full Text] [PDF]

				H. Z. Ring, C. N. Lessov, T. Reed, R. Marcus, L. Holloway, G. E. Swan, and D. Carmelli Heritability of Plasma Sex Hormones and Hormone Binding Globulin in Adult Male Twins J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3653 - 3658. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mikulec, K. H. Articles by Carmelli, D. Search for Related Content PubMed PubMed Citation Articles by Mikulec, K. H. Articles by Carmelli, D.